| Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small … H West, M McCleod, M Hussein, A Morabito, A Rittmeyer, HJ Conter, ... The Lancet Oncology 20 (7), 924-937, 2019 | 1540 | 2019 |
| Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial R Jotte, F Cappuzzo, I Vynnychenko, D Stroyakovskiy, ... Journal of Thoracic Oncology 15 (8), 1351-1360, 2020 | 517 | 2020 |
| Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up … BC Cho, DR Abreu, M Hussein, M Cobo, AJ Patel, N Secen, KH Lee, ... The Lancet Oncology 23 (6), 781-792, 2022 | 291 | 2022 |
| IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab+ carboplatin+ paclitaxel or nab-paclitaxel vs carboplatin+ nab-paclitaxel as 1L … RM Jotte, F Cappuzzo, I Vynnychenko, D Stroyakovskiy, DR Abreu, ... J clin oncol 36 (18 suppl), LBA9000, 2018 | 273 | 2018 |
| Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non–small-cell lung cancer: the phase III POSEIDON study ML Johnson, BC Cho, A Luft, J Alatorre-Alexander, SL Geater, ... Journal of Clinical Oncology 41 (6), 1213-1227, 2023 | 271 | 2023 |
| Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised … CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ... The Lancet Oncology 20 (3), 420-435, 2019 | 270 | 2019 |
| Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line … D Rodriguez-Abreu, ML Johnson, MA Hussein, M Cobo, AJ Patel, ... Journal of Clinical Oncology 38 (15_suppl), 9503-9503, 2020 | 267 | 2020 |
| Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non–small-cell lung cancer: CheckMate 153 DM Waterhouse, EB Garon, J Chandler, M McCleod, M Hussein, R Jotte, ... Journal of Clinical Oncology 38 (33), 3863-3873, 2020 | 188 | 2020 |
| Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non–small cell lung cancer, including patients … DR Spigel, M McCleod, RM Jotte, L Einhorn, L Horn, DM Waterhouse, ... Journal of Thoracic Oncology 14 (9), 1628-1639, 2019 | 186 | 2019 |
| Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial JM Weiss, T Csoszi, M Maglakelidze, RJ Hoyer, JT Beck, MD Gomez, ... Annals of Oncology 30 (10), 1613-1621, 2019 | 171 | 2019 |
| Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC) DR Spigel, M McLeod, MA Hussein, DM Waterhouse, L Einhorn, L Horn, ... Annals of Oncology 28, v461, 2017 | 120 | 2017 |
| PD-L1 expression by two complementary diagnostic assays and mRNA in situ hybridization in small cell lung cancer H Yu, C Batenchuk, A Badzio, TA Boyle, P Czapiewski, DC Chan, X Lu, ... Journal of Thoracic Oncology 12 (1), 110-120, 2017 | 120 | 2017 |
| Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study LL Hart, R Ferrarotto, ZG Andric, JT Beck, J Subramanian, ... Advances in therapy 38, 350-365, 2021 | 113 | 2021 |
| IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin+ nab-paclitaxel (CnP) with or without atezolizumab (atezo) as … F Cappuzzo, M McCleod, M Hussein, A Morabito, A Rittmeyer, HJ Conter, ... Annals of Oncology 29, viii742-viii743, 2018 | 88 | 2018 |
| PL02. 01 durvalumab±tremelimumab+ chemotherapy as first-line treatment for mNSCLC: results from the phase 3 POSEIDON study M Johnson, BC Cho, A Luft, J Alatorre-Alexander, SL Geater, K Laktionov, ... Journal of Thoracic Oncology 16 (10), S844, 2021 | 75 | 2021 |
| P3. 02c-026 is nivolumab safe and effective in elderly and PS2 patients with non-small cell lung cancer (NSCLC)? Results of CheckMate 153: Topic: IT D Spigel, L Schwartzberg, D Waterhouse, J Chandler, M Hussein, R Jotte, ... Journal of Thoracic Oncology 12 (1), S1287-S1288, 2017 | 63 | 2017 |
| Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial T Cascone, G Kar, JD Spicer, R García-Campelo, W Weder, DB Daniel, ... Cancer discovery 13 (11), 2394-2411, 2023 | 54 | 2023 |
| OA15. 04 association between KRAS/STK11/KEAP1 mutations and outcomes in POSEIDON: durvalumab±tremelimumab+ chemotherapy in mNSCLC S Peters, BC Cho, A Luft, J Alatorre-Alexander, SL Geater, SW Kim, ... Journal of Thoracic Oncology 17 (9), S39-S41, 2022 | 40 | 2022 |
| The McCAVE trial: vanucizumab plus mFOLFOX‐6 versus bevacizumab plus mFOLFOX‐6 in patients with previously untreated metastatic colorectal carcinoma (mCRC) JC Bendell, T Sauri, AC Gracián, R Alvarez, C López‐López, ... The oncologist 25 (3), e451-e459, 2020 | 39 | 2020 |
| NeoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage … T Cascone, R García-Campelo, J Spicer, W Weder, D Daniel, D Spigel, ... Cancer Res 82 (12_Supplement), CT011, 2022 | 29 | 2022 |
